Lymphoma

Product Candidate / PROGRAM Drug substance Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3/ Pivotal EMA/FDA review Commercial Rights
eryaspase (GRASPA® (1)) Asparaginase
Solid tumors

We are investigating the possibility to conduct clinical trials in one or more Non-Hodgkin Lymphoma (NHL) indications.

Top